Photo by nci from unsplash
5520Background: We previously demonstrated that bevacizumab may differentially improve ovarian cancer progression-free survival (PFS) depending on TCGA molecular subtypes. Despite recent progress i... Click to show full abstract
5520Background: We previously demonstrated that bevacizumab may differentially improve ovarian cancer progression-free survival (PFS) depending on TCGA molecular subtypes. Despite recent progress i...
Keywords:
survival improvement;
ovarian cancer;
cancer;
overall survival;
significant overall
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!